QT Vascular assures investors over suit
CEO: Minimal probability of a permanent injunction against its Chocolate PTA balloon catheter
Singapore
QT VASCULAR has assured investors in an update on the ongoing litigation involving specialty balloon angioplasty company AngioScore Inc during its annual general meeting on Thursday last week.
In June 2012, AngioScore initiated patent infringement proceedings against QT subsidiaries TriReme Medical and Quattro Vascular, as well as QT Vascular's chief executive Eitan Konstantino in relation to the Chocolate PTA balloon catheter. AngioScore's claim is that QT Vascular's Chocolate PTA infringes the '119 Patent - a patent that claims a very specific design for an angioplasty balloon catheter and a non-deployable stent.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Google, US clash over search advertising as trial winds down
Apple rallies most in 18 months on upbeat forecast, buyback
US: Wall St opens sharply higher on soft jobs data
HSBC has no plans to dispose of further businesses, chairman says
Glencore Group nears deal for Shell’s Singapore oil refinery
Chinese share of French EV market slumps after incentives curbed